Aptamers are single-stranded oligonucleotides that bind to their targets via specific structural
interactions. To improve the properties and performance of aptamers, modified nucleotides …

First studies on thrombin-inhibiting DNA aptamers were reported in 1992, and since then a
large number of anticoagulant aptamers has been discovered. TBA–also named HD1, a 15 …

Ligand/protein molecular recognition involves a dynamic process, whereby both partners
require a degree of structural plasticity to regulate the binding/unbinding event. Here, we …

In the past three decades, in vitro systematic evolution of ligands by exponential enrichment
(SELEX) has yielded many aptamers for translational applications in both research and …

Aptamers are single-stranded DNA or RNA sequences that bind target molecules with high
specificity and affinity. Aptamers exhibit several notable advantages over protein-based …

Despite their unquestionable properties, oligonucleotide aptamers display some drawbacks
that continue to hinder their applications. Several strategies have been undertaken to …

NU172—a 26-mer oligonucleotide able to bind exosite I of human thrombin and inhibit its
activity—was the first aptamer to reach Phase II clinical studies as an anticoagulant in heart …

Single-stranded DNA (ssDNA) oligonucleotides are widely used in biological research,
therapeutics, biotechnology, and nanomachines. Large-scale enzymatic production of …

The long-range communication between the two exosites of human α-thrombin (thrombin)
tightly modulates the protein-effector interactions. Duplex/quadruplex aptamers represent an …

Over the past few years, l-iminosugars have revealed attractive pharmacological properties
for managing rare diseases including Cystic Fibrosis (CF). The iminosugar N-butyl-l …